Ruboxistaurin (RBX) may prevent vision loss in diabetic patients
Phase III clinical trial of Ruboxistaurin (RBX) at a concentration of 32 milligrams/day// was found to inhibit Protein kinase C (PKC) – beta inhibitor, which was found to cause vision loss in patients with diabetes. The study was conducted in 252 patients with type 1 or type 2 diabetes by the Research team of Joslin Diabetes Centre across United States, Canada, Denmark, Netherlands and...Ruboxistaurin As A Novel Treatment For Diabetic Nephropathy
Recent research, which appears in the current issue of Diabetes Care, establishes Ruboxistaurin as a promising novel treatment that may improve upon established therapies for diabetic nephropathy//. Nephropathy is known to develop in 40% of people with type 2 diabetes and is the leading cause of end-stage renal disease in the U.S. and the developed world....